The FDA has approved Nuplazid (pimavanserin) tablets, from Acadia Pharmaceuticals, the first drug approved to treat hallucinations and delusions associated...
The NDA for Nuplazid (pimavanserin) from Acadia Pharma has been accepted for review by the FDA and the agency has...
Acadia Pharmaceuticals Inc. announced that the FDA Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of...
ACADIA Pharmaceuticals Inc. announced that the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive...
Acadia Pharmaceuticals presented positive top-line results from its Phase III HARMONY study of Nuplazid (pimavanserin) for the treatment of dementia-related...
Acadia Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA seeking approval for Nuplazid (pimavanserin) for the treatment...
Acadia Pharmaceuticals Inc.announced that the FDA has accepted for filing its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).
Acadia Pharmaceuticals announced that the Company has received a Complete Response Letter (CRL) from the FDA regarding its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).
Acadia Pharmaceuticals Inc. announced that it has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) to the FDA.
Acadia Pharmaceuticals Inc. has announced that it has received a target action date of August 4, 2022 from the FDA for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).